Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Iovance Biotherapeutics Q2 2024 Adj EPS $(0.34) Beats $(0.35) Estimate, Sales $31.11M Beat $24.59M Estimate

Author: Benzinga Newsdesk | August 08, 2024 04:27pm
Iovance Biotherapeutics (NASDAQ:IOVA) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.35) by 2.86 percent. The company reported quarterly sales of $31.11 million which beat the analyst consensus estimate of $24.59 million by 26.51 percent. This is a 12.97K percent increase over sales of $238.00 thousand the same period last year.

Posted In: IOVA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist